

Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: **10.08.2023**

State Party to the Convention: **ROMANIA**

Date of ratification/accession to the Convention: **25 July 1979**

National point of contact: **OSCE, Non-Proliferation and Arms Control Directorate**

Ministry of Foreign Affairs

Tel. : +40 21 431 1262, Fax: +40 21 431 1804

E-mail: don@mae.ro

Active promotion of contacts

The Third Review Conference agreed that States parties continue to implement the following:

"Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis."

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, the Seventh Review Conference encouraged States parties to share forward looking information, to the extent possible,

- on planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention, and
- on other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention,

including through the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs.

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention."

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO¹ Laboratory Biosafety Manual and/or OIE² Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Exchange of data on research centres and laboratories³

1. Name(s) of facility⁴ _____
2. Responsible public or private
organization or company _____
3. Location and postal address _____

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

¹ World Health Organization

² World Organization for Animal Health

³ The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

⁴ For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents⁶ on a State Party's territory:

I. The "Cantacuzino" National Medico-Military Institute for Research and Development ("Cantacuzino" NMMIRD)

Biosafety level 3 ⁷	yes (not operational/ requires validation)
Biosafety level 2 ⁸ (if applicable)	yes

Any additional relevant information as appropriate:

I. The "Cantacuzino" National Medico-Military Institute for Research and Development ("Cantacuzino" NMMIRD), located in Bucharest, operates several BSL2 containment laboratories (826.42 sqm) within the Service for Expertise and Intervention in Public Health (Viral Respiratory Infections Laboratory, Bacterial Respiratory Infections Laboratory, Viral Enteric Infections Laboratory, Vector-borne Infections Laboratory, Sexually and Parenterally Transmitted infections Laboratory, Bacterial Enteric Infections Laboratory, Nosocomial Infections Laboratory, Anaerobic and Zoonotic Infections Laboratory, Laboratory of Parasitology, Molecular Epidemiology of Transmissible Diseases Laboratory) and the Department of Research and Development.

These laboratories are used in diagnostic and surveillance of infectious diseases as well as in applied research activities, including test validation, test development and microbiological surveys of bacterial, viral and parasitic diseases. The primary objectives of these facilities are to provide a capability allowing Romania to:

⁵ In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

⁶ Microorganisms pathogenic to humans and/or animals

⁷ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

⁸ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

- Survey human health status in relation with circulating pathogenic strains (microbiological surveillance);

- Identification of strains of certain micro-organisms not usually found in Romania (as SARS-CoV-2 in 2020, 2021 or monkeypox virus in 2022).

“Cantacuzino” NMMIRD has a BSL3 facility (totalling 175 sqm) within the Service for Expertise and Intervention in Public Health, intended for diagnostic and applied research activities. Currently the BSL3 facility is not operational, as there still are several validation procedures to be performed.

“Cantacuzino” NMMIRD is not involved in any national biological defense research and development programme.

II. The National Institute for Infectious Diseases “Matei Balș” Bucharest (INBI MB)

Biosafety level 3 ⁹	yes (not operational/ requires validation)
Biosafety level 2 ¹⁰ (if applicable)	yes

Any additional relevant information as appropriate:

The National Institute for Infectious Diseases “Matei Balș” Bucharest (INBI MB) is the most important Romanian medical institution in charge with the management of patients with infectious diseases and consequently with victims of incidents involving biological agents. INBI MB is currently being designated by the Ministry of Health with the management of patients in case of out of the ordinary outbreaks (major, unusual, pandemic, such as the early stages of the Ebola epidemic in West Africa in 2014, when INBI MB was charged with the management of the suspect cases of Ebola on Romanian territory). INBI MB was involved in managing patients infected with SARS-CoV-2 from the very first case in Romania and was the leading institution that coordinates the national strategy on management of COVID-19 cases. INBI MB provides scientific counselling regarding infectious diseases policies in Romania for the Ministry of Health and also performs tasks related to first response in unusual outbreaks (such as the ones triggered by SARS, MERS CoV, H7N9 or H5N1 influenza viruses etc.). INBI MB functions as the seat for the National Anti-AIDS Commission (www.cnlas.ro), managing the prevention and treatment of AIDS on national level.

INBI MB is also involved in medical research, having a very modern Centre for Biomolecular Applied Research in Infectious Diseases, including BSL2 and BSL3 facilities. This laboratory facility is located in a 4 floor (plus a 5th technical floor) building with over 3300 sqm and has several dedicated areas for virology, bacteriology, molecular biology, genetics, immunology, clinical biochemistry as well as imagistics (radiology, CT, MRI etc. for patient use). These laboratories are employed in diagnostic and applied research activities, including test validation, test development and microbiological surveys. The primary objectives of these facilities are to provide a capability allowing Romania to:

⁹ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹⁰ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

- Survey human health status in relation with circulating pathogenic strains (microbiological surveillance);
- Identification of strains of certain micro-organisms not usually found in the country.

The BSL3 facilities are located at the second floor (areas dedicated to pathogenic fungi and Mycobacterium tuberculosis) but mainly at the 4th floor (540 sqm), with separated access from the ground level; it includes a HLCC (High Level of Containment Care) infected patient management area (unique in Romania, designed for managing at least 2 patients simultaneously, up to a maximum of 4) as well as a nearby BSL3+ laboratory (with both glove box and level A suit systems), suited for diagnostic activities involving highly dangerous pathogens, up to P4 (including some of the select agents that have the potential to pose a severe threat to public health and safety, such as the agents on Australia Group List). However, this capability refers mainly to diagnostic procedures performed on human biological samples (environmental samples will need further actions toward methods and techniques validation).

INBI MB has no operational BSL4 and is not involved in any national biological defense research and development program.

III. The Institute for Diagnosis and Animal Health

Biosafety level 3 ¹¹	yes
Biosafety level 2 ¹² (if applicable)	yes

Any additional relevant information as appropriate:

The Institute for Diagnosis and Animal Health maintains a High Containment Unit, designed to handle live foot-and-mouth disease virus for diagnosis purposes. IDAH is licensed to use FMDV by Commission Decision 339/2008.

IV. The Institute for Control of Veterinary Biological Products and Medicines (ICVBPM)

Biosafety level 3 ¹³	no
Biosafety level 2 ¹⁴ (if applicable)	yes

The **Institute for Control of Veterinary Biological Products and Medicines (ICVBPM)**, located in 39, Dudului Street, sector 6, Bucharest, Romania, is a unit with juridical status,

¹¹ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹² In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹³ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹⁴ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

functioning as a national reference institute, under the technical subordination of the National Sanitary Veterinary and Food Safety Authority.

ICVBPM has competence in the field of veterinary medicinal products, biocides, diagnosis sets, other veterinary products (vitamins, mineral supplements and cosmetics).

The main task with relevance on these issues is quality control of veterinary of live and inactivated vaccines for bacterial, viral, parasites:

- live vaccines against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus and parainfluenza in dogs,
- inactivated vaccine for rabies,
- live and inactivated vaccines for panleucopenia, calicivirus and herpesvirus infection of cats,
- live and inactivated vaccines for IBR, BVD and SRB of bovine,
- rabies live vaccine for oral immunization in foxes,
- live vaccines against Aujeszky virus for pigs,
- live vaccine against myxomatosis and inactivated vaccines for Infectious Rabbit Hemorrhagic Disease,
- live vaccine against infectious bronchitis in poultry, infectious bursitis in poultry (Gumboro disease), Newcastle disease in poultry, inactivated vaccine against the egg drop syndrome, Inactivated vaccine against Newcastle disease and infectious bursitis in poultry,
- vaccine against porcine parvovirus, inactivated,
- vaccine against leptospirosis in dogs and furry animals
- inactivated vaccine against equine influenza and tetanus,
- inactivated vaccines against parvovirus and swine erysipelas,
- live vaccine against anthrax with B. Anthracis, attenuated strain 1190 R,
- live vaccines for Salmonella in poultry.
- vaccine inactivated against avian Cholerae

Quality control of veterinary pharmaceutical products (antimicrobial, anti-inflammatory, antiparasitics, etc.). To perform the quality control of pharmaceutical products is used the microorganisms test as bellow:

- Staphylococcus aureus ATCC 6538,
- Bacillus subtilis ATCC 6633, NCTC 2589,
- Pseudomonasaeruginosa ATCC 9027,
- Clostridium sporogenes ATCC 11437,
- Candida albicans ATCC 10231,
- Aspergillus Brasiliensis ATCC16404,
- Escherichia coli ATCC 8739, ATCC 10536, ATCC 1133,
- Salmonella enterica subsp. Enterica serovariant typhimurium ATCC 14028,
- Saccharomyces cerevisiae ATCC 2601,
- Micrococcus luteus ATCC 10240, ATCC 9341,
- Bordetella bronchiseptica ATCC 4617,
- Bacillus pumilus NCTC 8241, CIP 76.18,
- Staphylococcus epidermitis NCIMB 8853, CIP 68.21, ATCC 12228,
- Candida tropicalis CIP 1433-83, NCCYC 1393,
- Bacillus spizizenii ATCC 4617,
- Streptococcus faecalis 8043.

Diagnostic test kits: for viral, bacterial and parasites disease by following tests: ELISA, immunodifusion test, complement bond reaction, slow and quick agglutination, immunofluorescent test, immunoperoxidase test.

Quality control of immunological veterinary medicinal products : Tuberculines avian and bovines(PPD)by using inactivated strains of Mycobacterium bovis and avium.

Any additional relevant information as appropriate:

The laboratories' s activities are organized and performed according to ISO 17025:2017 requirements and ISO 9001:2015 requirements.

V. The Institute for Hygiene and Veterinary Public Health (IHVPH)

Biosafety level 3 ¹⁵	no
Biosafety level 2 ¹⁶ (if applicable)	yes

Any additional relevant information as appropriate:

Institute for Hygiene and Veterinary Public Health (IHVPH) (located in Bucharest, Campul Mosilor street no. 5, sector 2, postal code 021201, Romania) is the public institution. Its source of financing comes only from the National Sanitary Veterinary and Food Safety Authority.

The Institute has a Microbiological section (Biosafety level 2), that includes 6 containment units with an approximate size of 150 m².

The Institute is the National Reference Laboratory in the field of animal origin products, food and animal feeding stuffs. Some of the main duties include activities of guidance, proficiency tests, technical co-ordination and control of the county Sanitary Veterinary Food Safety laboratories, sanitary veterinary expertise for animal origin foodstuffs, carrying out of results confirmation for laboratory testing, participation in the development of guidelines, instructions and technical details in the field of food safety and participation in the assessment proceedings for the authorization of veterinary microbiology laboratory.

The types of the micro-organisms used in daily activities are mentioned in the following table:

No.	Micro-organism	Reference
1.	<i>Aspergillus brasiliensis</i>	ATCC 16404
2.	<i>Aspergillus caesiellus</i>	ATCC 42693
3.	<i>Bacillus cereus</i>	ATTCC 11778
4.	<i>Bacillus subtilis</i> subsp. <i>spizizenii</i>	ATCC 6633
5.	<i>Candida albicans</i>	ATCC 10231
6.	<i>Campylobacter coli</i>	ATCC 43478
7.	<i>Campylobacter jejuni</i>	ATTC 33291
8.	<i>Campylobacter jejuni</i>	ATCC 29428
9.	<i>Campylobacter lari</i>	ATCC 35221
10.	<i>Citrobacter freundii</i>	ATCC 43864
11.	<i>Clostridium perfringens</i>	ATCC 13124
12.	<i>Clostridium botulinum</i> TIP F	NCTC 10281
13.	<i>Clostridium botulinum</i> TIP B	NCTC 7273
14.	<i>Clostridium botulinum</i> TIP E	NCTC 11219
15.	<i>Clostridium botulinum</i> TIP A	NCTC 11199
16.	<i>Clostridium butircum</i>	ATCC 19398
17.	<i>Cronobacter sakazakii</i>	ATCC 29544
18.	<i>Cronobacter muytjensii</i>	ATCC 51329
19.	<i>Enterobacter cloacae</i> subsp. <i>cloacae</i>	ATCC 13047

¹⁵ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹⁶ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

20.	<i>Enterococcus faecalis</i>	ATCC 19433
21.	<i>Enterococcus faecalis</i>	ATCC 29212
22.	<i>Enterococcus faecium</i>	ATCC 6057
23.	<i>Escherichia coli</i>	ATCC 8739
24.	<i>Escherichia coli</i>	NCTC 12900 (serotip O157:H7)
25.	<i>Escherichia coli</i>	NCTC 13216
26.	<i>Escherichia coli</i>	ATCC 25922
27.	<i>Listeria innocua</i> serotip 6a	ATCC 33090
28.	<i>Listeria ivanovii</i> subsp. <i>ivanovii</i>	ATCC 19119
29.	<i>Listeria monocytogenes</i> serotip 4b	ATCC 13932
30.	<i>Listeria monocytogenes</i> serotip 1a	ATCC 35152
31.	<i>Proteus mirabilis</i>	ATCC 29906
32.	<i>Pseudomonas aeruginosa</i>	ATCC 10145
33.	<i>Pseudomonas aeruginosa</i>	ATCC 27853
34.	<i>Rhodococcus equi</i>	ATCC 6939
35.	<i>Saccharomyces cerevisiae</i>	ATCC 9763
36.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Choleraesuis	ATCC 10708
37.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Choleraesuis	ATCC 7001
38.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Enteritidis	ATCC 13076
39.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Abaetetuba	ATCC 35640
40.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium	ATCC 14028
41.	<i>Staphylococcus aureus</i> subsp. <i>aureus</i>	ATCC 6538
42.	<i>Staphylococcus aureus</i> subsp. <i>aureus</i>	ATCC 25923
43.	<i>Staphylococcus epidermidis</i>	ATCC 12228
44.	<i>Vibrio cholerae</i>	NCTC 11348
45.	<i>Vibrio furnissii</i>	NCTC 11218
46.	<i>Vibrio parahaemolyticus</i>	NCTC 10884
47.	<i>Vibrio parahaemolyticus</i>	NCTC 10885
48.	<i>Vibrio parahaemolyticus</i>	NCTC 10903
49.	<i>Vibrio parahaemolyticus</i>	NCTC 10885
50.	<i>Vibrio parahaemolyticus</i>	ATCC 17802
51.	<i>Vibrio vulnificus</i>	NCTC 13647
52.	<i>Walleimia mellicola</i>	ATCC 42694
53.	<i>Yersinia enterocolitica</i> subsp. <i>enterocolitica</i>	ATCC 23715
54.	<i>Yersinia enterocolitica</i>	NCTC 11174
55.	<i>Yersinia enterocolitica</i>	NCTC 10598
56.	<i>Yersinia intermedia</i>	NCTC 11469
57.	<i>Yersinia pseudotuberculosis</i>	NCTC 10275
58.	<i>Yersinia enterocolitica</i> <i>palaearctica</i> O	NCTC 13769
59.	<i>E. coli</i> O103	ref. EURL <i>E. coli</i> B07
60.	<i>E. coli</i> O111	ref. EURL <i>E. coli</i> A07
61.	<i>E. coli</i> O157	ref. EURL <i>E. coli</i> C07
62.	<i>E. coli</i> O145	ref. EURL <i>E. coli</i> E07
63.	<i>E. coli</i> O26	ref. EURL <i>E. coli</i> D07
64.	<i>E. coli</i> O104:K-H12	ref. EURL <i>E. coli</i> H519
65.	<i>E. coli</i> O113:H21	ref. EURL <i>E. coli</i> 6182-50
66.	<i>E. coli</i> O55:H-	ref. EURL <i>E. coli</i> Su 3912-41

67	E. coli O121:K-:H10	ref. EURL E coli 39w
68	E. coli O128ab:H2	ref. EURL E coli Cigleris
69	E. coli O146:K-:H21	ref. EURL E coli CDC2950-54
70	E. coli O91:K-:H-	ref. EURL E coli H307B
71	E. coli O104:H4	ref. EURL E coli D4116
72	Salmonella Braenderup	ref. EURL E coli H9812
73	E. coli	ref. EURL SSI-NN14
74	E. coli	ref. EURL EA22
75	E. coli	ref. EURL SSI-OO15
76	E. coli	ref. EURL E coli D2653
77	E. coli	ref. EURL E coli D3602
78	E. coli	ref. EURL E coli D3522
79	E. coli	ref. EURL E coli D3428
80	E. coli	ref. EURL E coli D3648
81	E. coli	ref. EURL E coli D3546
82	E. coli	ref. EURL E coli D3509
83	E. coli	ref. EURL E coli D3431
84	E. coli	ref. EURL E coli D4134
85	Staphylococcus aureus	ref. EURL CPS FRI 137
86	Staphylococcus aureus	ref. EURL CPS FRI 361
87	Staphylococcus aureus	ref. EURL CPS A900322
88	Staphylococcus aureus	ref. EURL CPS FRI S6
89	Staphylococcus aureus	ref. EURL CPS FRI 326
90	Listeria monocytogenes	ref. Anses 00EB248LM ref. colectie Inst. Pasteur Clip74902
91	Listeria monocytogenes	ref. Anses 00EB249LM ref. colectie Inst. Pasteur Clip74903
92	Listeria monocytogenes	ref. Anses 00EB250LM ref. colectie Inst. Pasteur Clip74904
93	Listeria monocytogenes	ref. Anses 00EB254LM ref. colectie Inst. Pasteur Clip74908
94	Listeria monocytogenes	ref. Anses 00EB256LM ref. colectie Inst. Pasteur Clip74910
95	E. coli ESBL AmpC martor +	2005-10-96-1K99+ EURL AR
96	E. coli ESBL AmpC martor -	OXA-30 EURL AR
97	E. coli control CARBAPENEMAZE	TZ3638 EURL AR
98	E. coli control CARBAPENEMAZE	TZ 116 EURL AR
99	E. coli	ATCC 16874
100	Enterococcus faecalis	ATCC 29212 ref. EURL-AR
101	E. coli	ATCC 25922 ref. EURL-AR
102	Staphylococcus aureus	ATCC 29213 ref. EURL-AR
103	Salmonella infantis	ref. EURL Salmonella
104	Campylobacter jejuni	ATCC 33560 ref. EURL-AR
105	Bacillus cereus	NCTC 11143
106	Norovirus G I	lenticule disc-Certified Reference Material from Public Health England and reference materials from European Union Reference Laboratory for foodborne viruses
107	Norovirus G II	lenticule disc-Certified Reference Material from Public Health England and reference materials from European

		Union Reference Laboratory for foodborne viruses
108	Hepatitis A virus	lenticule disc-Certified Reference Material from Public Health England and reference materials from European Union Reference Laboratory for foodborne viruses
109	Clostridium botulinum type B	Strain isolated by IHVPH in food
110	Clostridium botulinum type E	Strain isolated by IHVPH in food
111	Clostridium botulinum TIP A	NCTC 11199 Public Health England
112	Clostridium botulinum type B	NCTC 7273 Public Health England
113	Clostridium botulinum type E	NCTC 7272 Public Health England
114	Clostridium botulinum type F	NCTC 10281 Public Health England
115	Vibrio vulnificus	NC 13647 Public Health England
116	Vibrio cholerae	NC 11348 Public Health England
117	Vibrio parahaemolyticus	NC 10885 Public Health England
118	Vibrio parahaemolyticus	NC 10884 Public Health England
119	Vibrio parahaemolyticus	NC 10903 Public Health England

VI. PASTEUR FILIPESTI SA BRANCH - WORKING POINT BUCHAREST

Biosafety level 3 ¹⁷	no
Biosafety level 2 ¹⁸ (if applicable)	yes

Any additional relevant information as appropriate:

PASTEUR FILIALA FILIPESTI SA - WORKING POINT BUCHAREST (address: 333, GIULESTI STR., 6TH SECTOR, POSTAL CODE 060269, BUCHAREST ROMANIA). Source(s) of financing: PASTEUR FILIALA FILIPESTI SA

Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Research regarding to animal viruses and bacteria: *Escherichia coli*, *Actinobacillus pleuropneumoniae*, *Erysipelothrix rhusiopathiae*, Aujeszky virus, avian laringotracheitis virus, avian coronavirus, avipox viruses, avian bursitis virus, avian paramyxoviruses, *Mycoplasma agalactiae*, *Clostridium perfringens*, *Clostridium septicum*, *Clostridium novyi*, *Clostridium chauvoei*, *Leptospira* spp.

Veterinary immunoprophylactic products, *in vivo* and *in vitro* diagnostic products.

Veterinary medicinal products.

The laboratories activities are organized in accordance to ISO 9001:2018 and for some of their methods to ISO 17025:2017 requirements.

¹⁷ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹⁸ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

- (1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;
- (2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;
- (3) The organizational structure of the programme and its reporting relationships; and
- (4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;
 - (a) location;
 - (b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;
 - (c) the total number of staff employed, including those contracted full time for more than six months;
 - (d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;
 - (e) a list of the scientific disciplines of the scientific/engineering staff;
 - (f) the source and funding levels in the following three areas: research, development, and test and evaluation; and
 - (g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes/No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.
2. State the total funding for each programme and its source.
3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes/No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?
5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.
6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).
7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
2. Where is it located (include both address and geographical location)?
3. Floor area of laboratory areas by containment level:
BL2 _____ (sqM)

BL3 _____ (sqM)
BL4 _____ (sqM)
Total laboratory floor area _____ (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel _____

(ii) Division of personnel:

Military _____

Civilian _____

(iii) Division of personnel by category:

Scientists _____

Engineers _____

Technicians _____

Administrative and support staff _____

(iv) List the scientific disciplines represented in the scientific/engineering staff.

(v) Are contractor staff working in the facility? If so, provide an approximate number.

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

(vii) What are the funding levels for the following programme areas:

Research _____

Development _____

Test and evaluation _____

(viii) Briefly describe the publication policy of the facility:

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms¹⁹ and/or toxins studied, as well as outdoor studies of biological aerosols.

¹⁹ Including viruses and prions.

Confidence-Building Measure "B"

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

At the Third Review Conference it was agreed that States Parties continue to implement the following:

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins, and on all such events that seem to deviate from the normal pattern as regards type, development, place, or time of occurrence. The information provided on events that deviate from the norm will include, as soon as it is available, data on the type of disease, approximate area affected, and number of cases.

The Seventh Review Conference agreed the following:

No universal standards exist for what might constitute a deviation from the normal pattern.

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

1. Exchange of data on outbreaks that seem to deviate from the normal pattern is considered particularly important in the following cases:

- When the cause of the outbreak cannot be readily determined or the causative agent²⁰ is difficult to diagnose,
- When the disease may be caused by organisms which meet the criteria for risk groups III or IV, according to the classification in the latest edition of the WHO Laboratory Biosafety Manual,
- When the causative agent is exotic to a given geographical region,
- When the disease follows an unusual pattern of development,
- When the disease occurs in the vicinity of research centres and laboratories subject to exchange of data under item A,
- When suspicions arise of the possible occurrence of a new disease.

2. In order to enhance confidence, an initial report of an outbreak of an infectious disease or a similar occurrence that seems to deviate from the normal pattern should be given promptly after cognizance of the outbreak and should be followed up by annual reports. To enable States Parties to follow a standardized procedure, the Conference has agreed that Form B should be used, to the extent information is known and/or applicable, for the exchange of annual information.

3. The declaration of electronic links to national websites or to websites of international, regional or other organizations which provide information on disease outbreaks (notably outbreaks of infectious diseases and similar occurrences caused by toxins that seem to deviate from the normal pattern) may also satisfy the declaration requirement under Form B.

²⁰ It is understood that this may include organisms made pathogenic by molecular biology techniques, such as genetic engineering.

4. In order to improve international cooperation in the field of peaceful bacteriological (biological) activities and in order to prevent or reduce the occurrence of ambiguities, doubts and suspicions, States Parties are encouraged to invite experts from other States Parties to assist in the handling of an outbreak, and to respond favourably to such invitations, respecting applicable national legislation and relevant international instruments.

Form B

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern²¹

1. Time of cognizance of the outbreak _____
2. Location and approximate area affected _____
3. Type of disease/intoxication _____
4. Suspected source of disease/intoxication _____
5. Possible causative agent(s) _____
6. Main characteristics of systems _____
7. Detailed symptoms, when applicable _____
 - respiratory _____
 - circulatory _____
 - neurological/behavioural _____
 - intestinal _____
 - dermatological _____
 - nephrological _____
 - other _____
8. Deviation(s) from the normal pattern as regards _____
 - type _____
 - development _____
 - place of occurrence _____
 - time of occurrence _____
 - symptoms _____
 - virulence pattern _____
 - drug resistance pattern _____
 - agent(s) difficult to diagnose _____
 - presence of unusual vectors _____
 - other _____
9. Approximate number of primary cases _____
10. Approximate number of total cases _____
11. Number of deaths _____
12. Development of the outbreak _____
13. Measures taken _____

²¹ See paragraph 2 of the chapeau to Confidence-Building Measure B.

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research.

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

• Published papers in ISI indexed journals generated through research and development activities performed within “Cantacuzino” NMMIRD in 2022

No	Title of the published scientific paper	Name of the Scientific Journal	Authors	Impact factor
1	Long-term treatment with chloroquine increases lifespan in middle-aged male mice possibly via autophagy modulation, proteasome inhibition and glycogen metabolism	Aging (Albany NY). 14, 10: 4195-4210 doi: 10.18632/aging.204069. 2022	Doepfner TR, Coman C, Burdusel D, Ancuta DL, Brockmeier U, Pirici DN, Yaoyun K, Hermann DM, Popa-Wagner A	5.68
2	Vaccine mRNA Can Be Detected in Blood at 15 Days Post-Vaccination.	Biomedicines2022,10, 1538 https://doi.org/10.3390/biomedicines10071538	Fertig, T.E.; Chitoiu, L.; Marta, D.S.; Ionescu, V.-S.; Cismasiu, V.B.; Radu, E.; Angheluta, G.; Dobre, M.; Serbanescu, A.; Hinescu, M.E.; Gherghiceanu, M.	5.61
3	Fever temperatures impair hemolysis caused by strains of Escherichia coli and	Heliyon 8 (2), (2022) e08958	Palela M, Giol ED, Amzuta A, Ologu O, Stan RC	3.78

No	Title of the published scientific paper	Name of the Scientific Journal	Authors	Impact factor
	Staphylococcus aureus			
4	Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS116-42 antigen	Front Immunol. 2022 Jul 22;13:941243. doi: 10.3389/fimmu.2022.941243. PMID: 35935966	Pantazica AM, Dobrica MO, Lazar C, Scurtu C, Tucureanu C, Caras I, Ionescu I, Costache A, Onu A, Clarke JL, Stavaru C, Branza-Nichita N.	7.56
5	Comparative study of useful compounds extracted from Lophanthus Anisatus by green extraction	Molecules 2022, 27, 7737, https://doi.org/10.3390/molecules27227737	Stefan, D.-S.; Popescu, M.; Luntraru, C.-M.; Suci, A.; Belcu, M.; Ionescu, L.-E.; Popescu, M.; Iancu, P.; Stefan, M.	4.93
6	Chitosan-Based Materials Featuring Multiscale Anisotropy for Wider Tissue Engineering Applications	International Journal of Molecular Sciences. 2022; 23(10):5336. https://doi.org/10.3390/ijms23105336	Vlăsceanu, G.M.; Ioniță, M.; Popescu, C.C.; Giol, E.D.; Ionescu, I.; Dumitrașcu, A.-M.; Floarea, M.; Boerasu, I.; Necolau, M.I.; Olăreț, E.; Ghițman, J.; Iovu, H	6.21
7	Hydroxyapatite from natural sources for medical applications	Materials (Basel)	Laura Madalina Cursaru, Miruna Iota, Roxana Mioara Piticescu, Daniela Tarnita, Sorin Vasile Savu, Ionel Dănuș Savu, Gabriela Dumitrescu, Diana Popescu, Radu-Gabriel Hertzog, Mihaela Calin	3.75
8	Descriptive statistics for plane structures of the multilayer matrix for tissue haemostasis and regeneration	Revista Industria Textila	Ene, A.G., Mihai, C., Visileanu, E., Vladu, A.F., Hertzog, R.-G., Popescu, D	0.83
9	On the adaptability of living organisms to stationary and non-stationary electromagnetic fields	IOP Conference Series: Materials Science and Engineering, 2022, DOI: 10.1088/1757-899x/1254/1/012024	Roșu G, Spandole-Dinu S, Catrina A-M, Tuță L, Baltag O, Fichte L O,	0.48
10	Fever as an evolutionary agent to select immune complexes interfaces	Immunogenetics 74, 465–474 (2022). https://doi.org/10.1007/s00251-022-01263-8	Tofan, V., Lenghel, A., de Camargo, M.M.	3.33
11	Generation of a 3D melanoma model and visualization of doxorubicin uptake by fluorescence imaging	In Vitro Cell.Dev.Biol.-Animal 58, 44–53 (2022). https://doi.org/10.1007/s11626-021-00636-9	Baciu, D. D., Dumitrașcu, A. M., Vasile, V., Palade, B., & Sălăgeanu, A.	2.72
12	Nickel (II) and cobalt (II) alginate biopolymers as a “carry and release” platform for polyhistidine-tagged proteins	Gels. 2022; 8(2):66. https://doi.org/10.3390/gels8020066	Dumitrașcu, A. M., Caraș, I., Tucureanu, C., Ermeneanu, A. L., & Tofan, V. C.	4.42
13	The activation of C–O bonds in lignin Miscanthus over acidic heterogeneous catalysts: towards	Biomass Conv. Bioref. (2022). https://doi.org/10.1007/s13	Samikannu, A., Mikkola, J. P., Tirsoaga, A., Tofan, V., Fierascu, R.	4.05

No	Title of the published scientific paper	Name of the Scientific Journal	Authors	Impact factor
	lignin depolymerisation to monomer units	399-022-03061-4	C., Richel, A., & Verziu, M. N.	
14	Characterization of Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Isolates from Two Romanian Hospitals Co-Presenting Resistance and Heteroresistance to Colistin	Antibiotics (Basel). 2022 Aug 30;11(9):1171. doi: 10.3390/antibiotics11091171. PMID: 36139950; PMCID: PMC949525	Földes A, Oprea M, Székely E, Usein CR, Dobreanu M	5.22
15	Using Rapid Analyte Measurement Platform (RAMP) as a Tool for an Early Warning System Assessing West Nile Virus Epidemiological Risk in Bucharest, Romania	Trop. Med. Infect. Dis. 2022, 7(11), 327; https://doi.org/10.3390/tropicalmed7110327 .	Prioteasa FL, Tiron GV, Dinu S, Fălcută E	3.71
16	Distribution of Insecticide Resistance Genetic Markers in the West Nile Virus Vector <i>Culex pipiens</i> from South-Eastern Romania	Insects 2022, 13(11), 1062; https://doi.org/10.3390/insects13111062 .	Stancu IG, Prioteasa FL, Tiron GV, Cotar AI, Fălcută E, Porea D, Dinu S, Ceianu CS, Csutak O	3.14
17	Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS116-42 antigen	Front Immunol. 2022 Jul 22;13:941243. doi: 10.3389/fimmu.2022.941243. PMID: 35935966	Pantazica AM, Dobrica MO, Lazar C, Scurtu C, Tucureanu C, Caras I, Ionescu I, Costache A, Onu A, Clarke JL, Stavaru C, Branza-Nichita N	8.79
18	Molecularly Imprinted Ligand-Free Nanogels for Recognizing Bee Venom-Originated Phospholipase A2 Enzyme	Polymers (Basel). 2022 Oct 7;14(19):4200. doi: 10.3390/polym14194200	Zaharia A, Gavrilă AM, Caras I, Trica B, Chiriac AL, Gifu CI, Neblea IE, Stoica EB, Dolana SV, Iordache TV	4.97
19	HT-29 Colon Cancer Cell Electromanipulation and Assessment Based on Their Electrical Properties	Micromachines (Basel). 2022 Oct 27;13(11):1833. doi: 10.3390/mi13111833	Olariu MA, Tucureanu C, Filip TA, Caras I, Salageanu A, Vasile V, Avram M, Tincu B, Turcan I	3.52
20	Optimisation of the rapid carbapenem inactivation method for use with AmpC hyperproducers	J Antimicrob Chemother. Letter to the Editor. 2022;77(4):1208-1209 https://doi.org/10.1093/jac/dkac058	I. Muntean MM, Muntean AM, Guérin F, Cattoir V, Creton E, Cotellon G, Oueslati S, Popa MI, Girlich D, Iorga B, Bonnin R, Naas T	5.76
21	Phenotypic and genotypic detection methods for antimicrobial resistance in ESKAPE pathogens	Exp Therap Med. 2022;24(2):508 https://www.spandidospublications.com/10.3892/etm.2022.11435 (ePub 9 June 2022) (autor corespondent)	Muntean MM, Muntean AA, Preda M, Manolescu L, Dragomirescu C, Popa MI, Popa GL	2.75
22	Temporo-spatial variations in resistance determinants and clonality of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> strains from Romanian hospitals and wastewaters	Antimicrob Resist Infect Control. 2022;11:115. https://doi.org/10.1186/s13756-022-01156-1	Gheorghe I, Czobor Barbu I, Popa LI, Gradisteanu Parcalabioru G, Popa M, Marutescu L, Nita-Lazar M, Banciu A, Stoica C, Gheorghe S, Lucaciu I, Sandulescu O,	6.45

No	Title of the published scientific paper	Name of the Scientific Journal	Authors	Impact factor
			Paraschiv S, Surleac M, Talapan D, Muntean AA, Preda M, Muntean MM, Dragomirescu CC, Popa MI, Otelea D, Chifiriuc MC	
23	Comment on A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A	Pathogens. 2022;11:751 https://doi.org/10.3390/pathogens1107075	Muntean AA, Munteam MM, Oueslati S, Bonnin R, Naas T, Popa MI	4.53
24	Pyridine Compounds with Antimicrobial and Antiviral Activities	Int j mol sci. 2022, 23, 5659, doi.org/10.3390/ijms23105659	Marinescu M. and Popa C.V.	6.21
25	Synthesis, characterization, DFT study and antifungal activities of some novel 2-(phenyldiazenyl)phenol based azo dyes	Materials, 2022,15(22), 8162, doi.org/10.3390/ma15228162	Marinescu, M., Popa, C.V., Tănase M.A., Soare A.C., Tablet C., Bala D., Cinteza L.O., Dițu L.M., Gifu I.C., Petcu C.	3.75
26	Responsible Research and Innovation associated to Risk Communication and Public Engagement on Health Emergency Preparedness at local level	Front Commun. 2022;7:827739 https://doi.org/10.3389/fcomm.2022.827739	Possenti V, De Mei B, Kurchatova A, Green M, KH Drager, Villa R, d'Onofrio A, Saadatian M, Moore V, Brattekas K, Karnaki P, Beresniak A, Popa MI, Greco D	2.10
27	Oxidative Stress in Chronic Hepatitis B – An Update	Microorganisms. 2022;10(7):1265 https://doi.org/10.3390/microorganisms10071265	Popa GL, Popa MI	4.93
28	An insight into the fecal microbiota composition in Romanian patients with ankylosing spondylitis using high-throughput 16S rRNA gene amplicon sequencing.	Rev Romana Med Lab. 2022;29(1):49-61. DOI:10.2478/rrlm-2022-0004	Oprea M, Cristea D, Dinu S, Ciontea SA, Bojinca VC, Predeteanu D, Balanescu A R, Usein CR	0.493
29	Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I-MOVE primary care multicentre study	Influenza Other Respi Viruses. 2022; 1- 10. doi:10.1111/irv.13069	Kissling, E, Pozo, F, Martínez-Baz, I, et al. (Romania: Lazăr M, Ivanciuc A, Mihai M.E)	4.38
30	Fatal Form of COVID-19 in a Young Male Bodybuilder Anabolic Steroid Using: The First Autopsied Case	Medicina https://doi.org/10.3390/medicina58101373	Siserman, C.V.; Jeican, I.I.; Gheban, D.; Anton, V.; Mironescu, D.; Șuşman, S.; Vică, M.L.; Lazăr, M.; Alua, M.; Toader, C	2.94
31	Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre	Eurosurveillance https://doi.org/10.2807/15607917.ES.2022.27.21.2101104	Kissling E, Hooiveld M, Martínez-Baz I, et al (Romania: Lazăr M, Cherciu C, Mihai M.E, Bistriceanu I, Ivanciuc	6.45

No	Title of the published scientific paper	Name of the Scientific Journal	Authors	Impact factor
	analysis, I-MOVE-COVID-19 and ECDC networks		A, Dintoi D, Pascu C, Jidovu A)	
32	Mind your Ps: A probabilistic model to aid the interpretation of molecular epidemiology data	eBioMedicine https://doi.org/10.1016/j.ebiom.2022.103989	Penedos A., Fernández-García A., Lazăr M, Ralh K, Williams D, Brown K	8.14
33	In Vivo Assessment Of Skin Chemical Burns In Exposure To Vesicants And The Efficacy Of An Antidote Formula In Different Pharmaceutical Forms. An Experimental Approach	FARMACIA, 2022, Vol. 70, 3 Approach https://doi.org/10.31925/farmacia.2022.3.11	Cristina Anca Secară , Ana Maria Catrina , Oana Cristina Voinea , Sonia Spandole Dinu, Andreea Camelia Hîrjău, Cerasela Haidoiu , Speranta Radu, C Mihail Silviu Tudosie	1.430

• Published papers in journals indexed in international databases generated through research and development activities performed within “Cantacuzino” NMMIRD in 2022

No	Title of the published scientific paper	Name of the Scientific Journal	Authors
1	Sheep General Anesthesia For Experimental Research Procedures	Scientific Papers. Series D. Animal Science. Vol. LXV, 1:267-272, ISSN 2285-5750; 2022	Ruxandra Costea, Ioana Ene, Tiberiu Iancu, Florin Posastiuc, Diana-Larisa Ancuta, Fabiola Ionita, Cristin Coman
2	- The rat as an animal model for the evaluation of the cutaneous wound healing	Scientific Works. Series C. Veterinary Medicine. Vol. LXVIII (1): 189-196, 2022	Fabiola Ioniță, Cristin Coman, Mario Codreanu
3	Histological evaluation of two euthanasia methods in a toxicity study in laboratory rats	Scientific Works. Series C. Veterinary Medicine. Vol. LXVIII (1): 183-188, 2022.	Cristin Coman, Diana Ancuța, Teodoru Soare
4	Popa GL, Popa MI. Shigellosis outbreaks – an update	Rom Archives Microbiol Immunol. 2022 (in press) accepted for publication	Popa GL, Popa MI
5	Pathways of transmission of antibiotic-resistant bacteria from hospitals to the aquatic environment	Viața Medicală. 2022;1692(28):10 https://viata-medicala.ro/campanii/cai-de-transmitere-a-bacteriilor-rezistente-la-antibiotice-din-spitale-in-mediul-acvatic-27859	Popa MI, Niță-Lazăr M, Oțelea D, Ficăi A, Grădișteanu G, Chifiriuc C
6	The unknowns of resistance to antibiotics and chemotherapy, elucidated by the RADAR project	Viața Medicală. 2022	Popa MI, Chifiriuc CM
7	The Covid-19 pandemic – a global statistical interpretation in first year dynamics	Romanian Journal Of Military Medicine Vol. CXXV, No.1 / 2022, February	Viorel Ordeanu, Lucia E. Ionescu
8	Therapeutic potential of hydrogels based on plant extracts and zinc oxide nanoparticles in skin lesions	Current Trends in Natural Sciences,	Ducu, C., Cirstea, G., Moga, S., Motea, M., Tudor, A., Popescu, D., Din, A., Vilcoci, D

No	Title of the published scientific paper	Name of the Scientific Journal	Authors
9	Medical intervention in the biological attack with Bacillus anthracis	Romanian Journal Of Military Medicine Vol. CXXV, No.1 / 2022, February	Viorel Ordeanu, Lucia E. Ionescu, Diana M. Popescu, Marius Necşulescu, Simona N. Bicheru, Gabriela V. Dumitrescu, Manuel Dogaru, Adrian A. Andrie

Published papers generated through research and development activities performed within The National Institute for Infectious Diseases “Matei Balş” (INBI MB) in 2022

Romania encourages publication of results of biological research directly related to the Convention, provided it is in compliance with good biosecurity practices. During the previous year, the research and development activities performed within INBI MB generated some published papers (ISI) to which Romania draws attention:

1. Gheorghita Jugulete, Daniela Pacurar, Mirela Luminita Pavelescu, Mihaela Safta, Elena Gheorghe, Bianca Borcos, Carmen Pavelescu, Mihaela Oros, Madalina Merisescu. *Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in children, a Romanian perspective*. Revista MDPI – Children, Impact Factor: 2.835 (2021) ; 5-Year Impact Factor: 3.328 (2021), ISSN: 2227-9067, ISI, Children 2022, 9, 1282. <https://doi.org/10.3390/children9091282>
2. Monica Neagu, Carolina Constantin, Gheorghita Jugulete, Victor Cauni, Sandrine Dubrac, Attila Gábor Szöllösi, Sabina Zurac. *Langerhans cells – revising their role in skin pathologies*. MDPI - Journal of Personalized Medicine (ISSN: 2075-4426), Impact Factor: 3.508, 5-year Impact Factor: 4.005, JCR category rank: Q2: Health Care Sciences & Services | Q2: Medicine, General & Internal, J.Pers.Med – 2081741, J. Pers. Med. 2022, 12, 2072. <https://doi.org/10.3390/jpm12122072> <https://www.mdpi.com/journal/jpm>
3. Reyes LF, Murthy S, Garcia-Gallo E, Irvine M, Merson L, Martin-Loeches I, Rello J, Taccone FS, Fowler RA, Docherty AB, Kartsonaki C, Aragao I, Barrett PW, Beane A, Burrell A, Cheng MP, Christian MD, Cidade JP, Citarella BW, Donnelly CA, Fernandes SM, French C, Haniffa R, Harrison EM, Ho AYW, Joseph M, Khan I, Kho ME, Kildal AB, Kutsogiannis D, Lamontagne F, Lee TC, Bassi GL, Lopez Revilla JW, Marquis C, Millar J, Neto R, Nichol A, Parke R, Pereira R, Poli S, Povaia P, Ramanathan K, Rewa O, Riera J, Shrapnel S, Silva MJ, Udy A, Uyeki T, Webb SA, Wils EJ, Rojek A, Olliaro PL; ISARIC Clinical Characterisation Group (Săndulescu O, et al). Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. ERJ Open Res. 2022 Feb 14;8(1):00552-2021. doi: 10.1183/23120541.00552-2021. IF(2022): 4.6 Q2.
4. Marwali EM, Kekalih A, Yulianto S, Wati DK, Rayhan M, Valerie IC, Cho HJ, Jassat W, Blumberg L, Masha M, Semple C, Swann OV, Kohns Vasconcelos M, Popielska J, Murthy S, Fowler RA, Guerguerian AM, Streinu-Cercel A, Pathmanathan MD, Rojek A, Kartsonaki C, Gonçalves BP, Citarella BW, Merson L, Olliaro PL, Dalton HJ; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Clinical Characterization Group Investigators (Săndulescu O, et al.). Paediatric COVID-19 mortality: a database analysis of the impact of health resource disparity. BMJ Paediatr Open. 2022;6(1):e001657. doi: 10.1136/bmjpo-2022-001657. eISSN: 2399-9772. IF(2021): 2.922.
5. Bouziotis J, Arvanitakis M, Preiser JC; ISARIC Clinical Characterisation Group (Săndulescu O et al). Association of body mass index with COVID-19 related in-hospital death. Clin Nutr. 2022 Dec;41(12):2924-2926. doi: 10.1016/j.clnu.2022.01.017. ISSN: 0261-5614. IF(2021): 7.643.
6. Wainstein M, MacDonald S, Fryer D, Young K, Balan V, Begum H, Burrell A, Citarella BW, Cobb JP, Kelly S, Kennon K, Lee J, Merson L, Murthy S, Nichol A, Semple MG, Strudwick S, Webb

- SA, Rossignol P, Claire-Del Granado R, Shrapnel S; ISARIC Clinical Characterisation Group (Săndulescu O et al). Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC-WHO clinical characterisation protocol. *PLoS Med.* 2022 Apr 20;19(4):e1003969. doi: 10.1371/journal.pmed.1003969. ISSN: 1549-1676 (online). IF(2021): 11.613.
7. Cho SM, White N, Premraj L, Battaglini D, Fanning J, Suen J, Bassi GL, Fraser J, Robba C, Griffiee M, Singh B, Citarella BW, Merson L, Solomon T, Thomson D; ISARIC Clinical Characterisation Group (Săndulescu O et al). Neurological manifestations of COVID-19 in adults and children. *Brain.* 2022 Sep 10;awac332. doi: 10.1093/brain/awac332. Online ISSN 1460-2156. Print ISSN 0006-8950. IF(2021): 15.255.
 8. Baruch J, Rojek A, Kartsonaki C, Vijayaraghavan BKT, Gonçalves BP, Pritchard MG, Merson L, Dunning J, Hall M, Sigfrid L, Citarella BW, Murthy S, Yeabah TO, Olliaro P, ISARIC Clinical Characterisation Group (Săndulescu O et al). Symptom-based case definitions for COVID-19: Time and geographical variations for detection at hospital admission among 260,000 patients. *Influenza Other Respir Viruses.* 2022;16:1040-1050. doi:10.1111/irv.13039. Online ISSN:1750-2659. IF(2021):5.606.
 9. Quéromès G, Frobert E, Burtseva E, Drăgănescu A, Koul PA, Komissarov A, Laguna-Torres VA, Leblanc J, López-Labrador FX, Medić S, Mironenko A, Otieno NA, Ruiz-Palacios GM, Md T, Ngs Team-Lyon, Gihsn Collaborators (Săndulescu O et al), Josset L, Lina B. Clinical and phylogenetic influenza dynamics for the 2019-20 season in the global influenza hospital surveillance network (GIHNS) - Pilot study. *J Clin Virol.* 2022 Jul;152:105184. doi: 10.1016/j.jcv.2022.105184. Online ISSN: 1873-5967. Print ISSN: 1386-6532. IF(2021):14.481.
 10. Rajendran NB, Arieti F, Mena-Benítez CA, Galia L, Tebon M, Alvarez J, Gladstone BP, Collineau L, De Angelis G, Duro R, Gaze W, Göpel S, Kanj SS, Käsbohrer, A, Limmathurotsakul D, Lopez de Abechuco E, Mazzolini E, Mutters NT, Pezzani MD, Presterl E, Renk H, Rodríguez-Baño J, Săndulescu O, Scali F, Skov R, Velavan TP, Vuong C, Tacconelli E, on behalf of the EPI-Net One Health consensus working group. EPI-Net One Health reporting guideline for antimicrobial consumption and resistance surveillance data: a Delphi approach. *Lancet Reg Health Eur.* 2022:100563. doi: 10.1016/j.lanepe.2022.100563. ISSN: 2666-7762. Web of Science Core Collection.
 11. Jordans CCE, Vasylyev M, Rae C, Jakobsen ML, Vassilenko A, Dauby N, Grevsen AL, Jakobsen SF, Raahauge A, Champenois K, Papot E, Malin JJ, Boender TS, Behrens GMN, Gruell H, Neumann A, Spinner CD, Valbert F, Akinosoglou K, Kostaki EG, Nozza S, Giacomelli A, Lapadula G, Mazzitelli M, Torti C, Matulionyte R, Matulyte E, Van Welzen BJ, Hensley KS, Thompson M, Ankiersztejn-Bartczak M, Skrzat-Klapaczyńska A, Săndulescu O, Streinu-Cercel Ad, Streinu-Cercel An, Miron VD, Pokrovskaya A, Hachfeld A, Dorokhina A, Sukach M, Lord E, Sullivan AK, Rokx C. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review. *Euro Surveill.* 2022;27(48):pii=2200338. doi: 10.2807/1560-7917.ES.2022.27.48.2200338. ISSN 1560-7917. IF(2021): 21.286.
 12. Matthews PC, Campbell C, Săndulescu O, Matičič M, Ruta SM, Rivero-Juárez A, van Welzen BJ, Tan BK, Garcia F, Gherlan GS, Çınar G, Hasanoğlu İ, Gmizić I, Nicolini LA, Santos L, Sargsyants N, Velikov P, Habibović S, Fourati S, Židovec-Lepej S, Herder V, Dudman S, Miron VD, Irving W, Şahin GÖ. Acute severe hepatitis outbreak in children: A perfect storm. What do we know, and what questions remain? *Front Pharmacol.* 2022;13:1062408. doi: 10.3389/fphar.2022.1062408. eISSN: 1663-9812. IF(2021): 5.988.
 13. Săndulescu O, Streinu-Cercel A, Miron VD, Apostolescu CG, Nițescu M, Drăgănescu AC, Streinu-Cercel A; ESCMID Study Group for Viral Hepatitis (ESGVH). Prevalence of undiagnosed hepatitis B virus infection in patients with COVID-19A single center retrospective study. *Medicine (Baltimore).* 2022 Nov 11;101(45):e31385. doi: 10.1097/MD.00000000000031385. Online ISSN: 1536-5964. IF(2021): 1.817.

14. Sandulescu O, Viziteu I, Streinu-Cercel A, Miron VD, Preoteşcu LL, Chirca N, Albu SE, Craiu M, Streinu-Cercel A. Novel antimicrobials, drug delivery systems and antivirulence targets in the pipeline—from bench to bedside. *Appl Sci.* 2022;12:11615. doi: 10.3390/app122211615. ISSN/eISSN: 2076-3417. IF(2021): 2.838.
15. Gonçalves BP, Hall M, Jassat W, Balan V, Murthy S, Kartsonaki C, Semple MG, Rojek A, Baruch J, Reyes LF, Dasgupta A, Dunning J, Citarella BW, Pritchard M, Martín-Quiros A, Sili U, Baillie JK, Aryal D, Arabi Y, Rashan A, Angheben A, Caoili J, Carrier FM, Harrison EM, Gómez-Junyent J, Figueiredo-Mello C, Douglas JJ, Mat Nor MB, Chow YP, Wong XC, Bertagnolio S, Thwin SS, Streinu-Cercel A, Salazar L, Rishu A, Rangappa R, Ong DSY, Hashmi M, Carson G, Diaz J, Fowler R, Kraemer MUG, Wils EJ, Horby P, Merson L, Olliaro PL; ISARIC Clinical Characterisation Group (Sandulescu O et al.). An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. *Elife.* 2022 Oct 5;11:e80556. doi: 10.7554/eLife.80556. ISSN: 2050-084X. IF (2021): 8.713.
16. Săndulescu O. Back-to-school for university students – can infectious diseases be taught online? *GERMS.* 2022;12(3):332. doi: 10.18683/germs.2022.1336. ISSN: 2248-2997. Web of Science Core Collection.
17. Gheorghe-Barbu I, Barbu IC, Popa LI, Pircălăbioru GG, Popa M, Măruţescu L, Niţă-Lazar M, Banciu A, Stoica C, Gheorghe Ş, Lucaciu I, Săndulescu O, Paraschiv S, Surleac M, Talapan D, Muntean AA, Preda M, Muntean MM, Dragomirescu CC, Popa MI, Oţelea D, Chifiriuc MC. Temporo-spatial variations in resistance determinants and clonality of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* strains from Romanian hospitals and wastewaters. *Antimicrob Resist Infect Control.* 2022 Sep 14;11(1):115. doi: 10.1186/s13756-022-01156-1. ISSN: 2047-2994. IF (2021): 6.454.
18. Reyes LF, Murthy S, Garcia-Gallo E, Merson L, Ibáñez-Prada ED, Rello J, Fuentes YV, Martín-Loeches I, Bozza F, Duque S, Taccone FS, Fowler RA, Kartsonaki C, Gonçalves BP, Citarella BW, Aryal D, Burhan E, Cummings MJ, Delmas C, Diaz R, Figueiredo-Mello C, Hashmi M, Panda PK, Jiménez MP, Rincon DFB, Thomson D, Nichol A, Marshall JC, Olliaro PL; ISARIC Characterization Group (Săndulescu O, et al.) Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study. *Crit Care.* 2022 Sep 13;26(1):276. doi: 10.1186/s13054-022-04155-1. ISSN: 1364-8535. IF (2021): 19.334.
19. Kim JY[#], Săndulescu O[#], Preotescu LL[#], Rivera-Martínez NE, Dobryanska M, Birlutiu V, Miftode EG, Gaibu N, Caliman-Sturdza O, Florescu SA, Shi HJ, Streinu-Cercel A, Streinu-Cercel A, Lee SJ, Kim SH, Chang I, Bae YJ, Suh JH, Chung DR, Kim SJ, Kim MR, Lee SG, Park G, Eom JS. A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. *Open Forum Infect Dis.* 2022 Aug 8;9(8):ofac406. doi: 10.1093/ofid/ofac406. (#Contribuţii e-gale). Online ISSN 2328-8957. IF (2021): 4.433.
20. Streinu-Cercel A, Miron VD, Oană AA, Irimia M, Popescu RS, Dărămuş IA, Moţoi MM, Ceapraga GJ, Săndulescu O. Real-world use of molnupiravir in the treatment of outpatients with SARS-CoV-2 infection—A patient profile based on the experience of a tertiary infectious disease center. *Pharmaceuticals.* 2022;15:1065. doi: 10.3390/ph15091065. EISSN:1424-8247. IF (2021): 5.215.
21. ISARIC Clinical Characterization Group (Sandulescu O et al), Garcia-Gallo E, Merson L, Kennon K, Kelly S, Citarella BW, Fryer DV, Shrapnel S, Lee J, Duque S, Fuentes YV, Balan V, Smith S, Wei J, Gonçalves BP, Russell CD, Sigfrid L, Dagens A, Olliaro PL, Baruch J, Kartsonaki C, Dunning J, Rojek A, Rashan A, Beane A, Murthy S, Reyes LF. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19. *Sci Data.* 2022 Jul 30;9(1):454. doi: 10.1038/s41597-022-01534-9. ISSN online: 2052-4463. IF (2021): 8.501.
22. Şahin GÖ, Mondelli MU, Matičić M, Sandulescu O, Irving W; ESCMID Study Group for Viral Hepatitis (ESGVH). Acute severe hepatitis of unknown aetiology in children: a new non-A-E

- hepatitis virus on horizon? *Clin Microbiol Infect.* 2022 Sep;28(9):1300-1301. doi: 10.1016/j.cmi.2022.05.001. ISSN: 1198-743X. Impact factor (2021): 13.310.
23. Vasylyev M, Skrzat-Klapaczyńska A, Bernardino JI, Săndulescu O, Gilles C, Libois A, Curran A, Spinner CD, Rowley D, Bickel M, Aichelburg MC, Nozza S, Wensing A, Barber TJ, Waters L, Jordans C, Bramer W, Lakatos B, Tovba L, Koval T, Kyrychenko T, Dumchev K, Buihichyk V, Smyrnov P, Antoniak S, Antoniak S, Vasylyeva TI, Mazhnaya A, Kowalska J, Bhagani S, Rokx C; European AIDS Clinical Society (EACS) Young Investigators (YING). Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine. *Lancet HIV.* 2022 Jun;9(6):e438-e448. doi: 10.1016/S2352-3018(22)00125-4. ISSN 2352-3018. Impact factor (2021): 16.070.
 24. Crăciun MD, Nițescu GV, Golumbeanu M, Tănase AA, Pițigoi D, Săndulescu O, Crăciun P, Enciu BG, Bălănescu RN, Ulici A. mRNA COVID-19 Vaccine Reactogenicity among Healthcare Workers: Results from an Active Survey in a Pediatric Hospital from Bucharest, January-February 2021. *Vaccines (Basel).* 2022 May 25;10(6):836. doi: 10.3390/vaccines10060836. EISSN 2076-393X. Impact factor (2021): 4.961.
 25. Săndulescu O. The renewed threat of vaccine-preventable diseases in the war-struck European continent. *Germs.* 2022 Mar 31;12(1):7-9. doi: 10.18683/germs.2022.1301. ISSN: 2248-2997. Web of Science Core Collection.
 26. Streinu-Cercel A[#], Săndulescu O[#], Preotescu LL[#], Kim JY, Kim YS, Cheon S, Jang YR, Lee SJ, Kim SH, Chang I, Suh JH, Lee SG, Kim MR, Chung DR, Kim HN, Streinu-Cercel A, Eom JS. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. *Open Forum Infect Dis.* 2022 Feb 2;9(4):ofac053. doi: 10.1093/ofid/ofac053. Online ISSN 2328-8957. Factor de impact (2021): 4.433. [#]Co-prim author.
 27. Miguez-Rey E, Choi D, Kim S, Yoon S, Săndulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. *Expert Opin Investig Drugs.* 2022 Jan;31(1):41-58. doi: 10.1080/13543784.2022.2030310. ISSN: 1354-3784, eISSN: 1744-7658. Impact factor (2021): 6.498, Q1. WOS: 000755469900001
 28. Enciu BG, Draganescu AC, Pitigoi D, Sandulescu O, Craciun MD, Bilasco A, Streinu-Cercel A, Streinu-Cercel A, Florea D, Miron VD, Arama V. Comparative Analysis of Clinical and Epidemiological Characteristics in Patients with SARI Confirmed as Influenza or COVID-19 Admitted in a Tertiary Care Hospital in Bucharest, Romania. *Processes.* 2022;10(2):327. doi:10.3390/pr10020327. ISSN: 2227-9717. Impact factor (2022): 3.5 Q3. WOS: 000762189800001 (contribuții egale)
 29. Streinu-Cercel A[#], Săndulescu O[#], Miron VD, Paraschiv S, Casangiu C, Hohan R, Bănică L, Surleac M, Streinu-Cercel A. Undetected Omicron Transmission in Romania—Report of the First Detected Case of Locally Acquired Omicron Infection and Complete Epidemiological Investigation. *Diagnostics (Basel).* 2022;12:348. doi: 10.3390/diagnostics12020348. ISSN: 2075-4418. Factor de impact: 3.992 (2021), Q2. ([#]co-first authors). WOS: 000762078400001
 30. Stan IV, Miron VD, Vangheli IA, Gheorghiu RM, Streinu-Cercel A, Săndulescu O, Craiu M. First Case of COVID-19 Treated with Monoclonal Anti-Spike Antibodies in a Patient with Cystic Fibrosis in Romania. *Diagnostics (Basel).* 2022 Jan 7;12(1):137. doi: 10.3390/diagnostics12010137. ISSN: 2075-4418. Factor de impact: 3.992 (2021), Q2. WOS: 000747112300001. (contribuții egale)
 31. Anghel, Ana-Maria-Jennifer; Niculae, Cristian-Mihail; Manea, Eliza-Daniela; Lazar, Mihai; Popescu, Mara; Damalan, Anca-Cristina; Bel, Adela-Abigaela; Nedelcu, Iulia-Maria; Patrascu, Raluca-Elena; Hristea, Adriana, *The Impact of Tocilizumab on Radiological Changes Assessed by Quantitative Chest CT in Severe COVID-19 Patients*, JOURNAL OF CLINICAL MEDICINE, 2022 11(5) IF 4.964 10.3390/jcm11051247
 32. Niculae, Cristian-Mihail; Anghel, Ana-Maria-Jennifer; Militaru, Eliza-Daniela; Tirlescu, Laura-Georgiana; Lazar, Mihai; Hristea, Adriana *Acute Pulmonary Artery Thrombosis despite*

Anticoagulation in Patients with COVID-19 Pneumonia: A Single-Center Retrospective Cohort Study, JOURNAL OF CLINICAL MEDICINE, 2022, 11 (9) IF 4.964 10.3390/jcm11092633

33. Pinte, Larisa; Ceasovschih, Alexandr; Niculae, Cristian-Mihail; Stoichitoiu, Laura Elena; Ionescu, Razvan Adrian; Balea, Marius Ioan; Cernat, Roxana Carmen; Vlad, Nicoleta; Padureanu, Vlad; Purcarea, Adrian; Badea, Camelia; Hristea, Adriana; Sorodoc, Laurentiu; Baicus, Cristian, *Antibiotic Prescription and In-Hospital Mortality in COVID-19: A Prospective Multicentre Cohort Study*, JOURNAL OF PERSONALIZED MEDICINE 2022, 12 (6) IF=3.508 10.3390/jpm12060877
34. Stoichitoiu, Laura Elena; Pinte, Larisa; Ceasovschih, Alexandr; Cernat, Roxana Carmen; Vlad, Nicoleta Dorina; Padureanu, Vlad; Sorodoc, Laurentiu; Hristea, Adriana; Purcarea, Adrian; Badea, Camelia; Baicus, Cristian *In-Hospital Antibiotic Use for COVID-19: Facts and Rationales Assessed through a Mixed-Methods Study* JOURNAL OF CLINICAL MEDICINE, 2022 11(11) IF 4.964 10.3390/jcm11113194
35. Kunze, Michael; Banovic, Pavle; Bogovic, Petra; Briciu, Violeta; Civljak, Rok; Dobler, Gerhard; Hristea, Adriana; Kerlik, Jana; Kuivanen, Suvi; Kyncl, Jan; Lebech, Anne-Mette; Lindquist, Lars; Paradowska-Stankiewicz, Iwona; Roglic, Srdan; Smiskova, Dita; Strle, Franc; Vapalahti, Olli; Vranjes, Nenad; Vynograd, Nataliya; Zajkowska, Joanna Maria; Pilz, Andreas; Palmborg, Andreas; Erber, Wilhelm *Recommendations to Improve Tick-Borne Encephalitis Surveillance and Vaccine Uptake in Europe* MICROORGANISMS 2022, 10 (7) IF=4.92 10.3390/microorganisms10071283
36. Lazar, Mihai; Barbu, Ecaterina Constanta; Chitu, Cristina Emilia; Anghel, Ana-Maria-Jennifer; Niculae, Cristian-Mihail; Manea, Eliza-Daniela; Damalan, Anca-Cristina; Bel, Adela-Abigaela; Patrascu, Raluca-Elena; Hristea, Adriana; Ion, Daniela Adriana, *Pericardial Involvement in Severe COVID-19 Patients*, MEDICINA-LITHUANIA 2022 58(8), IF 2.43, 10.3390/medicina58081093
37. Lazar, Mihai; Barbu, Ecaterina Constanta; Chitu, Cristina Emilia; Anghel, Ana-Maria-Jennifer; Niculae, Cristian-Mihail; Manea, Eliza-Daniela; Damalan, Anca-Cristina; Bel, Adela-Abigaela; Patrascu, Raluca-Elena; Hristea, Adriana; Ion, Daniela Adriana, *Mortality Predictors in Severe SARS-CoV-2 Infection* MEDICINA-LITHUANIA 2022, 58 (7) 10.3390/medicina58070945
38. Neurological manifestations of SARS-Cov2 infection: a narrative review. Pavel B, Moroti R, Spataru A, Popescu MR, Panaitescu AM, Zagrean AM. Brain Sci. 2022, 12, 1531. <https://doi.org/10.3390/brainsci12111531> IF=3.333
39. Factors leading to dissemination of cutaneous anthrax: an international ID-IRI study. Elbahr US, Tekin R, Papić M, Pandak N, Erdem H, Can FK, [...] Moroti R, [...] Giammanco A. New Microbes New Infect. 2022 Sep 7;48:101028 <https://doi.org/10.1016/j.nmni.2022.101028> PMID: 36193102; PMCID: PMC9526185 IF=0.67
40. Wiessing L, Sypsa V, Abagiu AO, Arble A, Berndt N, Bosch A, Buskin S, Chemtob D, Combs B, Conyngham C, Feelemyer J, Fitzgerald M, Goldberg D, Hatzakis A, Patrascu RE, Keenan E, Khan I, Konrad S, Leahy J, McAuley A, Menza T, Merrick S, Metcalfe R, Rademaker T, Revivo S, Rosca P, Seguin-Devaux C, Skinner S, Smith C, Tinsley J, Wilberg M, Des Jarlais D. Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and Israel. AIDS Behav. 2023 Apr;27(4):1140-1153. doi: 10.1007/s10461-022-03851-x. Epub 2022 Nov 11. PMID: 36367613; PMCID: PMC9651099. IF 2022= 4.4
41. Bogdan Nițescu, Daniela Pițigoi * , Daniela Tălăpan* , Maria Nițescu, Sorin Ștefan Aramă, Bogdan Pavel, Adrian Streinu-Cercel, Alexandru Rafila and Victoria Aramă. “Etiology and Multi-Drug Resistant Profile of Bacterial Infections in Severe Burn Patients, Romania 2018–2022”. Articol publicat in revista Medicina 2023(MDPI), Vol. 59 (issue 6), 1143. Pag. 1-12. ISSN: 1648-9144 IF 2022= 2.6 <https://doi.org/10.3390/medicina59061143> <https://www.mdpi.com/1648-9144/59/6/1143>

42. Bogdan Nitescu, Bogdan Pavel, Irina Andra Tache, Ioana Anastasia Pop, Cosmin Ion Balan, Stefan Sorin Arama, Sebastian Isac, Adrian Streinu-Cercel, Talapan Daniela, Pitigoi Daniela, Victoria Arama. "Predictive values of presepsin and c-reactive protein on prognosis in severe burns". Articol publicat in revista FARMACIA, 2023, Vol. 71, 3, Pag: 511-517. ISSN: 0014-8237 IF 2022 (2023 update)=1.6 <https://doi.org/10.31925/farmacia.2023.3.8> https://farmaciajournal.com/wp-content/uploads/art-08-Nitescu_Pavel_Arama_511-517.pdf
43. Nicoleta Mihai, Mihai Lazăr, Catalin Tilișcan, Ecaterina Constanța Barbu, Cristina Emilia Chițu, Laurențiu Stratan, Oana Alexandra ganea, Sorin Ștefan Aramă, Daniela Adriana Ion, Victoria Aramă. *Predictors of Liver Injury in Hospitalized Patients with SARS-CoV-2 Infection*. Revista MEDICINA 2022, Vol. 58 (issue 12), 1714. Pag. 1-16. ISSN: 1648-9144. IF 2022= 2.6 <https://doi.org/10.3390/medicina58121714> <https://www.mdpi.com/1648-9144/58/12/1714>
44. Mihai N, Tiliscan C (autor corespondent), Visan CA, Stratan L, Ganea O, Arama SS, Lazar M, Arama V. *Evaluation of Drug-Induced Liver Injury in Hospitalized Patients with SARS-CoV-2 Infection*. Microorganisms 2022, 10(10), 2045. Pag: 1-13. ISSN: 2076-2607 IF 2022= 4.5 <https://doi.org/10.3390/microorganisms10102045>
45. Georgeana Țuculeanu, Ecaterina Constanța Barbu, Mihai Lazăr, Cristina Emilia Chițu-Tișu, Cristina Mihaela Olariu, Mihai Bojincă, Cătălin Tilișcan, Ștefan Sorin Aramă, Victoria Aramă, Daniela Adriana Ion. "*Reduced bone mineral density in young, non-cirrhotic patients with chronic viral hepatitis*". Revista FARMACIA, 2022, Vol. 70, 2, pag.279-286. ISSN: 0014-8237 IF 2022 (2023 update)= 1.6 <https://doi.org/10.31925/farmacia.2022.2.13>
46. Laurențiu Mihăiță Stratan, Cătălin Tilișcan, Mihai Lazăr, Constanța Angelica Vișan, Sorin Ștefan Aramă, Nicoleta Mihai, Oana Ganea, Victoria Aramă, Andreea Letiția Arsene, Daniela Adriana Ion. "*Real-life comparison of Tocilizumab and Anakinra associated with corticosteroid use in a cohort of hospitalized patients with SARS-CoV-2 infection*". FARMACIA, 2022, Vol. 70, 1. PP.17-22 ISSN: 0014-8237 IF 2022 (2023 update)= 1.6 <https://doi.org/10.31925/farmacia.2022.1.3>
47. Bianca Georgiana Enciu, Alina Andreea Tănase, Anca Cristina Drăgănescu, Victoria Aramă, Daniela Pițigoi and Maria-Dorina Crăciun. The COVID-19 Pandemic in Romania: A Comparative Description with Its Border Countries. Revista Healthcare, 2022, 10, 1223. Pag.1-8. ISSN: 2227-9032 IF 2022=2.8 <https://doi.org/10.3390/healthcare10071223> <https://www.mdpi.com/journal/healthcare>
48. Mihai Lazar, Ecaterina Constanta Barbu, Cristina Emilia Chitu, Catalin Tiliscan, Laurentiu Stratan ,Sorin Stefan Arama , Victoria Arama and Daniela Adriana Ion. "Interstitial Lung Fibrosis Following COVID-19 Pneumonia". Revista DIAGNOSTICS 2022, vol.12, issue 8,2028 (publicat in august 2022).
ISSN: 2075-4418 IF 2022=3.6 <https://doi.org/10.3390/diagnostics12082028>
49. Haeuser E, Serfes AL, Cork MA, Preotescu L, Dwyer-Lindgren L; Local Burden of Disease sub-Saharan Africa HIV Prevalence Collaborators. Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018. BMC Med. 2022 Dec 19;20(1):488. doi: 10.1186/s12916-022-02639-z. ISSN 1741-7015. IF(2021): 11.806
50. Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, Compton K, **Preotescu L**, Force LM. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022 Mar 1;8(3):420-444. doi: 10.1001/jamaoncol.2021.6987. IF(2021):33.012.

Research projects performed in INBI MB during 2022 with topics related to the BWTC:

1. REVERSE pREvention and management tools for rEducing antibiotic Resistance in high prevalence SETting, Contract nr. 965265 Cod proiect: H2020-SC1-2020-Singe-Stage-RTD/E60; 2021-2026, Hristea Adriana - director partener (UMFCD) in the European consortium, Horizon 2020 <https://umfcd.ro/cercetare-si-dezvoltare/proiecte/proiecte-internationale/reverse-h2020-sc1-bhc-2018-2020-h2020-sc1-2020-single-stage-rtd-prevention-and-management-tools-for-reducing-antibiotic-resistance-in-high-prevalence-settings/>
2. “Development of Robust and Innovative Vaccine Effectiveness (DRIVE)”, financed through the Innovative Medicines Initiative (IMI) 2 Grant Agreement No. 777363. Project partner: The National Institute for Infectious Diseases “Matei Balș”. Responsabil partener: Dr. Anca Drăgănescu. Rol în proiect: Investigator principal adulți. Project coordinator: Fundación Para el Fomento de Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spania. Buget partener: 87 000 EUR. Octombrie 2021 – Iunie 2022. Roluri in proiect: Daniela Pitigoi (Tehnicul Project Manager pentru partener INBI Prof. Dr. Matei Balș); Oana Sandulescu (Investigator principal pentru adulți); Victoria Arama (Membru în echipa de cercetare. Investigator principal).
3. Grant “GIHSN prospective epidemiological active surveillance study in Romania”. Global Influenza Hospital Surveillance Network (GIHSN) 2022-2023. Finanțare: Foundation for influenza epidemiology, Fondation de France. Beneficiar: Institutul Național de Boli Infecțioase “Prof. Dr. Matei Balș”. Director de proiect: Dr. Anca Drăgănescu. Buget: 69 000 EUR. noiembrie 2022 – 2023. Roluri in proiect: Daniela Pitigoi (Tehnicul Project Manager pentru partener INBI Prof. Dr. Matei Balș); Oana Sandulescu (Membru în echipa de cercetare); Victoria Arama (Investigator principal)
4. Grant “GIHSN prospective epidemiological active surveillance study in Romania”. Global Influenza Hospital Surveillance Network (GIHSN) 2021-2022. Finanțare: Foundation for influenza epidemiology, Fondation de France. Beneficiar: Institutul Național de Boli Infecțioase “Prof. Dr. Matei Balș”. Director de proiect: Dr. Anca Drăgănescu. Buget: 110 800 EUR. octombrie 2021 – octombrie 2022. Roluri in proiect: Daniela Pitigoi (Tehnicul Project Manager pentru partener INBI Prof. Dr. Matei Balș); Oana Sandulescu (Membru în echipa de cercetare); Victoria Arama (Investigator principal)
5. University Medical Center Utrecht. Multi-centre EuRopean study of MAJOR Infectious Disease Syndromes (MERMAIDS) – Acute Respiratory Infections (MERMAIDS ARI) 2.0. Funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003589. 2020 – 2022. Rol in proiect: Oana Sandulescu- Investigator principal.
6. “Selecția și diseminarea genelor de rezistență la antibiotice de la nivelul stațiilor de epurare a apelor uzate în mediul acvatic și sectorul clinic” – “Selection and dissemination of antibiotic resistance genes from water treatment stations for aquatic medium and clinical sector” (RADAR). PN-III-P4-ID-PCCF-2016-0114. Finanțare de la bugetul de stat prin PNCDI III, Programul 4 “Cercetare fundamentală și de frontieră”, Proiecte complexe de cercetare de frontieră. Partener în proiect: Institutul Național de Boli Infecțioase “Prof. Dr. Matei Balș”. Responsabil partener: Prof. Dr. Adrian Streinu-Cercel. Coordonator proiect: Universitatea București. Buget: 8.500.000 RON (1.888.888,89 EUR). Buget partener: 1.650.000 RON (366.666,67 EUR). August 2018 – 2022. Rol in proiect: Oana Sandulescu- Membru în echipa de proiect.
7. Explorarea influenței microbiotei tractului digestiv și a stării de imunitate preexistente la agenții patogeni respiratori asupra rezultatului infecției cu SARS-CoV-2 (Exploring the influence of digestive microbiota and preexisting immunity status to respiratory pathogens on SARS-CoV-2 infection) .

Responsabil proiect: Prof. Univ. Dr. Veronica Lazăr, Facultatea de Biologie, Univ. București. Instituție coordonatoare: Facultatea de Biologie, Univ. București.

Parteneri: University of Montreal, Canada - Prof. Petronela Ancuța, Professor of Immunology-Virology, Depart. of Microbiology, Infectiology and Immunology. Faculty of Medicine; Institutul Național de Boli Infecțioase Prof. Dr. Matei Baș (I.N.B.I.M.B) – Prof. Univ. Dr. Victoria Aramă, MD; Institutul de Virusologie St. Nicolau (I.V.N.) – Prof. univ. dr. Simona Ruță, MD; Spitalul Clinic Colțea (S.C.C.) – Șef de Lucrări dr. Raluca Grigore, MD; Spitalul Județean de Urgență Ploiești (S.J.U.P.)– Șef Laborator Clinic, Biolog dr. Claudia Vlad. Rol in proiect: Victoria Arama- Director proiect pentru partenerul INBIMB. Perioada desfășurării: iunie 2021- iulie 2022

8. D-SOLVE -Understanding Individual Host Response against Hepatitis D virus to develop a personalized approach for the management of Hepatitis D. Horizon Europe Framework Programme NO 101057917, CO-PI: Conf. Univ. Dr. Florin Alexandru Căruntu. Echipă de proiect: Dr. Monica Nicoleta Radu, Dr. Corina Tudoran, Dr. Rareș-Bogdan Băloi

9. Proiect CRDF Global - Disrupting the Rise of Disinformation Campaigns in the Biological Sphere Through Grants and Mentorship , titlu The deleterious effect on public health of the disinformation by omission in vaccination campaigns, project director Anca Streinu-Cercel, in parteneriat cu SNSPA Bucuresti, grant castigat mai 2023 at <https://www.crdglobal.org/grants/fellowships-funding-opportunities>

10. Study Number: 209668 Title: Phase 2b multi-center, randomised, partial-blind parallel cohort study to assess the efficacy and safety of treatment with bepirovirsen in participants with chronic hepatitis B virus (B-clear)

11. GS-US-611-6273 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression

Confidence-Building Measure "D"

(Deleted)

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

(a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also

on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures ²²	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	<u>Yes/No</u>	<u>Yes/No</u>	<u>Yes/No</u>	<u>Yes/No</u>
(b) Exports of micro-organisms ²³ and toxins	<u>Yes/No</u>	<u>Yes/No</u>	Yes/ <u>No</u>	<u>Yes/No</u>
(c) Imports of micro-organisms ¹¹ and toxins	<u>Yes/No</u>	Yes/ <u>No</u>	Yes/No	Yes/ <u>No</u>
(d) Biosafety ²⁴ and biosecurity ²⁵	Yes/No	Yes/No	Yes/No	Yes/No

Name of legislation, regulations and other measures

No	Specification	No	Year	Topic
1	Regulation (EU) 2021/821 of the European Parliament and of the Council	821	2021	Setting up a Union regime for the control of exports, brokering, technical assistance, transit and transfer of dual-use items
2	Commission Delegated Regulation (EU) 2023/006	996	2023	Amending Regulation (EU) 2021/821 of the European Parliament and of the Council as regards the list of dual-use items
3	Government Emergency Ordinance	43	2022	Regarding the control regime of dual use operations
4	Law	235	2022	Approving Government Emergency Ordinance No. 43/2022
5	Order of the Minister of Foreign Affairs	1205	2022	For the approval of the norms for the application of the Government Emergency Ordinance No. 43/2022 regarding the control regime of dual-use items operations

²² Including guidelines.

²³ Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

²⁴ In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

²⁵ In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

6	Government Emergency Ordinance	158	1999	On the control regime of exports, imports and other operations with military products, republished on August 2, 2021
7	Order of the Minister of Foreign Affairs	3191	2021	For the approval of the Norms for the application of the Government Emergency Ordinance no. 158/1999
8	Decision of the Government of Romania	476	2023	For the approval of the List containing the military products subject to the control regime of exports, imports and other operations.

Confidence-Building Measure "F"

Declaration of past activities in offensive and/or defensive biological research and development programmes

In the interest of increasing transparency and openness, States parties shall declare whether or not they conducted any offensive and/or defensive biological research and development programmes since 1 January 1946.

If so, States parties shall provide information on such programmes, in accordance with Form F.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State Party.
2. Past offensive biological research and development programmes:
 - Yes/No
 - Period(s) of activities
 - Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.
3. Past defensive biological research and development programmes:
 - Yes/No
 - Period(s) of activities
 - Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

I. Declaration of vaccine production facilities

1. Name of facility: PASTEUR FILIALA FILIPESTI S.A, Working Point Bucharest
2. Location (mailing address): 333, Giulesti Str., 060269 Bucharest, 6th Sector, Romania, phone: +40212209909; fax: +40212206915; email: office@pasteur.ro
3. General description of the types of diseases covered: Antravac – live antrax vaccine for animals: cattle, horses, sheep, goats and swine
- animal diseases (viral, bacterial diseases).

II. Declaration of vaccine production facilities

1. Name of facility: ROMVAC COMPANY S.A.
 2. Location (mailing address): Soseaua Centurii, No. 7 Voluntari, postal code 077190, Romania (romvac@romvac.ro)
 3. General description of the types of diseases covered: Carboromvac – live antrax vaccine for animals: cattle, sheep, goats, horses and swine.
- animal diseases (viral, bacterial diseases).
-